Dear ASPS Community Members,
Through the shared experiences, updates, and my private communications with ASPS patients who were previously participating in a Cediranib Clinical Trial and then unfortunately developed resistance to the Cediranib, it has become very evident that rapid and aggressive rebound and disease progression can/does sometime occur following discontinuation of the Cediranib. Based on this very concerning anecdotal data, I feel that it is extremely important that everyone who is currently taking Cediranib be very aware of the possibility of rebound, and that they have a plan in place to begin another systemic treatment as soon as possible after discontinuing the Cediranib if that becomes necessary, to try to prevent the rapid and aggressive post-Cediranib disease progression that has devastatingly been experienced by several ASPS patients on this Board.
It is critically important to everyone in the ASPS Community who is closely following this promising drug, for all of the ASPS patients or family members of ASPS patients who have previously taken, or are currently taking Cediranib to write to share their Cediranib treatment experience, results, and any anecdotal information regarding rebound experience. None of us have the luxury of waiting for all of the Cediranib Clinical Trial data to be gathered, documented, and published in an official report, which sometimes can take several years, so the best and most up-to-date information that is currently available to all of us must come from shared indivdual patient experience.
Take care everyone, and please try to actively participate on the Board with updated shared information as your time and situation allow.
With special concern, caring thoughts, and continued Hope,
Bonni
Need for awareness & vigilance regarding possible rebound
One of the most promising trials currently open.
-
- Senior Member
- Posts: 1678
- Joined: Mon Aug 14, 2006 11:32 pm
- Location: Sammamish, WA USA
Jump to
- Welcome to CureASPS.org!
- ↳ Guest Book
- ↳ Forum Issues and Suggestions
- News and Updates
- ↳ Personal Stories and Updates
- ↳ Success Stories
- ↳ Rest In Peace
- ↳ Anonymous Patient Updates
- ↳ Chinese group news
- ↳ Medical Publications
- ↳ Other Publications
- ↳ Sarcoma Meetings and Conferences
- ASPS Clinical Trials
- ↳ Other Clinical Trials
- ↳ COMPLETED - ARQ 197 Clinical Trial
- ↳ COMPLETED - Dana Farber Vaccine Clinical Trial (GVAX)
- ↳ Dasatinib
- ↳ Alisertib
- ↳ Cediranib
- ↳ Anlotinib
- ↳ Immune checkpoint inhibitors (ICI)
- ↳ Axitinib and Pembrolizumab (Keytruda) in Miami, US
- ↳ TECENTRIQ (atezolizumab) by Genentech
- ↳ Pfizer's PF-06801591
- ↳ Durvalumab+Tremelimumab at MDACC
- Symptoms and Diagnostics
- ↳ Symptoms
- ↳ Scan Types and Follow-Up
- ↳ Molecular Studies
- ↳ Pathology results
- Primary Tumor Treatment
- ↳ Resection
- ↳ Treatment of Non-Resectable Primary Tumor
- ↳ Radiation
- Systemic Treatment
- ↳ TKI
- ↳ Sutent (sunitinib)
- ↳ Pazopanib
- ↳ Сabozantinib (Cometriq)
- ↳ Sorafenib
- ↳ Chemotherapy
- ↳ Metronomic chemotherapy
- ↳ Temozolomide (Temodar)
- ↳ Side effects of systemic treatments
- ↳ Interferon alpha
- ↳ Immune checkpoint inhibitors ICI (PD-1 and PD-L1 targeting drugs)
- ↳ Keytruda
- ↳ Opdivo
- ↳ TECENTRIQ (atezolizumab)
- ↳ Toxicity, problems and potentiation strategies
- ↳ Treatment response criteria and evaluation/scanning problems/rare cases
- ↳ treatment discontinuation/re-treatment
- Metastatic Disease Treatment
- ↳ Local treatment modalities
- ↳ cryoablation
- ↳ Side effects/complications of the local ablations
- ↳ Radiosurgery
- ↳ Microwave ablation
- ↳ High intensity focused ultrasound (HIFU)
- ↳ Lung Metastases
- ↳ Laser assisted surgery
- ↳ Brain Metastases
- ↳ Bone Metastases
- ↳ Other Metastases
- ↳ Abdominal Metastases
- ↳ Liver metastases
- ↳ Heart Metastases
- ↳ Spinal metastases
- ↳ Adrenal metastases
- ↳ Pancreatic metastases
- Living with ASPS
- ↳ Insurance Coverage
- ↳ Second opinion from a sarcoma center
- ↳ Finanical assistance
- ↳ Diet and lifestyle
- ↳ Related studies
- ↳ Pain management
- ↳ Travel assistance